astragaloside a has been researched along with Disease Models, Animal in 79 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (1.27) | 29.6817 |
| 2010's | 44 (55.70) | 24.3611 |
| 2020's | 34 (43.04) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, Y; Gao, F; Wang, J; Wang, X; Xu, W; Zhu, G | 1 |
| Kasetti, RB; Kodati, B; Maddineni, P; Nagarajan, B; Yacoub, S | 1 |
| Li, Y; Liu, D; Liu, W; Wan, Q; Xiao, Q; Xiong, Y; Zhao, H; Zhong, Y; Zhou, W | 1 |
| Feng, Y; Gao, X; Hao, X; Li, L; Long, Y; Zhang, J; Zhang, S; Zhang, X | 1 |
| Chen, BY; Chen, CH; Liou, JC; Wu, JL; Yang, SL | 1 |
| He, Y; Huang, B; Huang, J; Meng, Y; Shen, F; Wang, L | 1 |
| Liu, Y; Lu, ML; Tang, BL; Wang, HX | 1 |
| Chen, L; Chen, Y; Dong, S; He, C; Jiang, S; Tao, S; Tian, L | 1 |
| Hu, K; Liu, M; Ni, S; Sun, L; Wang, J; Xu, X; Zhao, X | 1 |
| Chen, Y; Li, P; Liang, J; Luo, X; Wang, Q; Xie, X; Yang, C; Zhang, M; Zhou, L | 1 |
| Chen, Y; Huang, S; Le, B; Li, S; Li, W; Mo, Y; Pan, H; Wang, Q; Wang, S; Wei, R; Wen, H; Xu, E; Yang, C; Zheng, J | 1 |
| Fang, Y; He, Y; Li, C; Wan, H; Yang, J; Yin, F; Yu, L; Zhou, H | 1 |
| Chen, X; Gao, W; Gu, M; Hu, S; Huang, C; Lin, H; Lin, J; Pan, X; Shao, Z; Tian, N; Wang, B; Wang, X; Wu, Y; Zhang, X; Zheng, X; Zhou, Y | 1 |
| Feng, K; Tang, Y; Tao, R; Wei, Y; Wu, Y; Xu, H; Zhao, Y | 1 |
| Huang, H; Liu, W; Xu, Z | 1 |
| Ding, L; Geng, L; Hu, X; Li, M; Wang, Z; Xie, S; Yang, T | 1 |
| Liang, YN; Niu, YC; Zhang, J; Zhao, XM | 1 |
| Chen, HY; Chen, WC; Chen, YH; Liu, PL | 1 |
| Ding, R; Fang, H; Ge, R; Huang, J; Wang, E; Wang, J; Wang, L; Wang, T; Zhai, M; Zhou, P | 1 |
| Guo, Y; Jin, Y; Li, L; Wei, J; Zhao, Y | 1 |
| Jia, L; Liang, C; Ni, GX; Shi, XL; Wang, YL | 1 |
| Ge, B; Li, FR; Li, SL | 1 |
| Deng, LL | 1 |
| Chen, Y; Niu, Y; Wang, Q; Xu, H; Xue, C; Zhao, RC; Zhu, R | 1 |
| Song, L; Xing, B; Yang, S; Zhang, P; Zhang, R; Zhou, L | 1 |
| Abulikemu, Z; Aierken, R; Dilixiati, N; Huang, Y; Li, XY; Sui, S; Tuerxun, D; Zhang, YM | 1 |
| Jin, S; Liu, X; Promes, V; Tian, Y; Zhang, Y | 1 |
| Huang, D; Pei, C; Wang, F; Wang, M; Wang, X; Wang, Z; Wu, Y; Xiao, W | 1 |
| Dong, YJ; Du, SJ; Gao, WJ; Tang, JL; Zhang, Y; Zhao, YM; Zhou, XH | 1 |
| Chu, L; Fang, Y; Gan, H; Hu, X; Jin, H; Li, L; Yang, Y; Zhang, J | 1 |
| Du, J; Jin, H; Ren, H; Wang, W; Yang, G | 1 |
| Han, Z; Zhu, J | 1 |
| Chai, YH; Chen, YZ; Gao, J; Jiang, ZB; Li, W; Luo, YF | 1 |
| Guo, LH; Huang, X; Liu, B; Ma, SY; Yin, X; Zhang, MZ | 1 |
| Chen, F; Cheng, XY; Li, J; Liu, HT; Wang, R; Yang, D; Yang, H; Yang, XH; Yao, Y; Zheng, P | 1 |
| Cao, T; Chen, H; Dong, Z; Guo, W; Lu, R; Tian, J; Wei, H; Xu, M; Zhang, C; Zhao, P | 1 |
| Chen, D; Chen, Y; Jiang, R; Li, D; Li, J; Li, K; Li, X; Liu, Z; Wang, H; Xiong, W; Yuan, K | 1 |
| Dai, R; Fang, Z; Huang, K; Qin, S; Yin, J | 1 |
| Chen, Y; Du, Y; Wan, Q; Wu, J; Xu, Y; Zhu, X | 1 |
| Tan, HY; Tang, B; Wei, XQ; Zhang, JG | 1 |
| Qi, R; Tuerdi, N; Wan, Y; Wang, Y; Xu, L; Ye, M | 1 |
| Ma, Y; Qiao, G; Yin, Y; Yu, X; Yu, Y; Zhang, Y | 1 |
| Ding, Y; Huang, W; Ji, L; Li, L; Liu, C; Sun, K; Tumen, B; Wang, S; Zhang, L; Zhang, W | 1 |
| Pan, H; Rui, R; Sun, B; Wang, X; Zhang, L | 1 |
| Gao, Y; Tian, N; Wang, T; Wang, X; Wu, B; Xu, J; Zhang, N; Zhu, Z | 1 |
| Kan, P; Wang, J; Xiang, L; Xu, N; Yang, P; Yao, X; Zhu, Y | 1 |
| Bian, Y; Chen, J; Chen, L; Chen, Y; Pan, Y; Shen, Y; Song, Z; Wei, D | 1 |
| Ma, Y; Xiong, L | 1 |
| Gao, Y; Shi, Y; Tian, N; Wang, T; Wang, X; Wu, B; Xu, J | 1 |
| Liu, F; Liu, L; Sui, YB; Wang, Y; Zhang, YQ | 1 |
| Dong, Y; Liu, J; Liu, T; Liu, X; Ma, R; Niu, H; Sun, J; Wang, Y; Xiao, Y; Xiao, Z; Yang, F; Zhang, M | 1 |
| Guo, Y; Liu, G; Song, J; Wang, T; Zhou, Z | 1 |
| Du, M; Gao, Y; He, Y; Liu, H; Wang, H; Wang, Z; Wu, X | 1 |
| Chen, K; Feng, L; Guo, F; Huang, C; Li, Y; Liu, X; Wang, R; Wu, Y; Zhu, W | 1 |
| Kim, MH; Kim, SH; Yang, WM | 1 |
| Chi, YF; Peng, W; Wang, L; Yin, PH; Yuan, ZT; Zhang, XM; Zhou, WC | 1 |
| Cai, H; Chi, YF; Peng, W; Wang, L; Yin, PH; Yuan, ZT; Zhang, XM; Zhou, WC | 1 |
| Bian, T; Du, Q; Gao, F; Qian, XF; Qiu, YY; Shi, LZ; Sun, H; Yu, MH; Yuan, MY; Zhu, JX | 1 |
| Chang, CK; Chang, CP; Chiu, BY; Hsu, YC; Lin, JW; Yang, ST | 1 |
| Cha, X; Li, D; Mao, Y; Qi, Q; Yi, J; Zhu, K | 1 |
| Chen, GQ; Gu, DM; Lu, PH; Sun, M; Wang, Q; Wang, X; Zhang, K | 1 |
| Cheng, L; Fan, Y; Hu, G; Jia, R; Ma, X; Qiu, L; Sun, R; Tang, M; Wang, X; Xiao, W; Xing, M; Yin, G; Yu, G; Zhao, Y | 1 |
| Chen, D; Cheng, L; Pan, JH; Wang, ZS; Xie, XH; Xiong, F | 1 |
| Cai, GJ; Chen, YF; Fan, R; Gao, Y; Hou, MX; Shi, GB; Song, J; Wang, Q; Wang, TC; Yang, C; Zhang, W | 1 |
| Chen, M; Li, H; Li, X; Luo, X; Wan, H; Xia, T; Zhang, Y | 1 |
| Dong, W; Geng, L; Li, M; Qin, A; Qin, Y; Wang, W; Zhang, M; Zhang, X | 1 |
| Jiang, W; Wang, HD; Yu, JM; Zhang, XB; Zhang, YN | 1 |
| Deng, BX; Deng, CQ; Ding, H; Huang, XP; Lu, JD; Tang, YH | 1 |
| Du, M; He, YX; Huang, F; Lan, YY; Liu, HS; Peterson, KE; Shi, HL; Wang, ZT; Woods, T; Wu, H; Wu, XJ; Zhang, BB | 1 |
| Chang, CP; Chio, CC; Lin, HJ; Lin, MT | 1 |
| Liang, P; Zhao, XM; Zhou, NN; Zhu, R | 1 |
| Deng, X; Fang, F; Li, H; Li, M; Ma, S | 1 |
| Chen, YY; Fan, JY; Han, JY; Jiang, XG; Li, C; Liu, YY; Mu, HN; Sun, K; Wang, CS; Wang, MX; Yan, L | 1 |
| Dai, J; Guo, X; Hoffman, RM; Sun, YU; Tang, D; Yang, Z; Yin, G; Zang, W; Zhang, S | 1 |
| Sun, S; Sun, Y; Wang, S; Yuan, X | 1 |
| He, Q; Lai, H; Wang, J; Xiong, M | 2 |
| Li, J; Lu, J; Wan, H; Yang, J; Zhang, Y; Zhu, Z | 1 |
| Chen, J; Ding, D; Fu, JH; Hong, Z; Luo, Y; Qin, Z; Zhang, WD; Zhang, X | 1 |
1 review(s) available for astragaloside a and Disease Models, Animal
| Article | Year |
|---|---|
Evaluation of astragaloside IV in hepatic fibrosis: A meta-analysis.
Topics: Animals; Cell Line; Disease Models, Animal; Drugs, Chinese Herbal; Liver; Liver Cirrhosis; Male; Rats; Saponins; Triterpenes | 2021 |
78 other study(ies) available for astragaloside a and Disease Models, Animal
| Article | Year |
|---|---|
Depichering the Effects of Astragaloside IV on AD-Like Phenotypes: A Systematic and Experimental Investigation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Astragalus propinquus; Computational Biology; Disease Models, Animal; Drugs, Chinese Herbal; Hippocampus; Male; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Network Pharmacology; Neuroinflammatory Diseases; Peptide Fragments; Phenotype; Phosphorylation; Phytotherapy; PPAR gamma; Pyroptosis; Saponins; Signal Transduction; Support Vector Machine; tau Proteins; Triterpenes | 2021 |
Astragaloside IV Attenuates Ocular Hypertension in a Mouse Model of TGFβ2 Induced Primary Open Angle Glaucoma.
Topics: Animals; Aqueous Humor; Disease Models, Animal; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Mice; Ocular Hypertension; Saponins; Trabecular Meshwork; Transforming Growth Factor beta2; Triterpenes | 2021 |
Astragaloside Ⅳ alleviates ulcerative colitis by regulating the balance of Th17/Treg cells.
Topics: Animals; Colitis; Colitis, Ulcerative; Colon; Cytokines; Dextran Sulfate; Disease Models, Animal; Mice; Mice, Inbred C57BL; Saponins; T-Lymphocytes, Regulatory; Th17 Cells; Triterpenes | 2022 |
Astragaloside IV in Hypoxic Pulmonary Hypertension: an In Vivo and In Vitro Experiments.
Topics: Animals; Disease Models, Animal; Hypertension, Pulmonary; Hypoxia; Monocrotaline; Rats; Saponins; Tumor Necrosis Factor-alpha | 2022 |
Photoreceptor and vision protective effects of astragaloside IV in mice model with light-evoked retinal damage.
Topics: Animals; Disease Models, Animal; Mice; Retinal Cone Photoreceptor Cells; Retinal Degeneration; Saponins; Triterpenes | 2022 |
Antihypertension effect of astragaloside IV during cerebral ischemia reperfusion in rats.
Topics: Animals; Brain Ischemia; Disease Models, Animal; Infarction, Middle Cerebral Artery; Rats; Rats, Sprague-Dawley; Reperfusion; Reperfusion Injury; Saponins; Triterpenes | 2023 |
Astragaloside IV improves pulmonary arterial hypertension by increasing the expression of CCN1 and activating the ERK1/2 pathway.
Topics: Animals; Disease Models, Animal; Endothelial Cells; Epidermal Growth Factor; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Hypoxia; Male; MAP Kinase Signaling System; Oxygen; Pulmonary Arterial Hypertension; Pulmonary Artery; Rats; Rats, Sprague-Dawley | 2023 |
Astragaloside IV regulates TL1A and NF-κB signal pathway to affect inflammation in necrotizing enterocolitis.
Topics: Animals; Animals, Newborn; Disease Models, Animal; Enterocolitis, Necrotizing; Inflammation; Ligands; NF-kappa B; Rats; Rats, Sprague-Dawley; Signal Transduction | 2023 |
Nose to brain delivery of Astragaloside IV by β-Asarone modified chitosan nanoparticles for multiple sclerosis therapy.
Topics: Animals; Brain; Chitosan; Disease Models, Animal; Mice; Multiple Sclerosis | 2023 |
Astragaloside IV inhibits AOM/DSS-induced colitis-associated tumorigenesis via activation of PPARγ signaling in mice.
Topics: Animals; Azoxymethane; Carcinogenesis; Cell Transformation, Neoplastic; Colitis; Dextran Sulfate; Disease Models, Animal; Inflammation; Mice; Mice, Inbred C57BL; PPAR gamma; Reactive Oxygen Species | 2023 |
Astragaloside IV ameliorates motor deficits and dopaminergic neuron degeneration via inhibiting neuroinflammation and oxidative stress in a Parkinson's disease mouse model.
Topics: Animals; Anti-Inflammatory Agents; Cell Line; Disease Models, Animal; Dopaminergic Neurons; Inflammasomes; Lipopolysaccharides; Male; Mice, Inbred C57BL; Microglia; Motor Activity; MPTP Poisoning; Neuroprotective Agents; NF-E2-Related Factor 2; NLR Family, Pyrin Domain-Containing 3 Protein; Oxidative Stress; Rats; Saponins; Triterpenes | 2019 |
Astragaloside IV alleviates ischemia reperfusion-induced apoptosis by inhibiting the activation of key factors in death receptor pathway and mitochondrial pathway.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Brain; Brain Infarction; Disease Models, Animal; Male; Mitochondria; Neuroprotective Agents; Rats, Sprague-Dawley; Receptors, Death Domain; Reperfusion Injury; Saponins; Signal Transduction; Triterpenes | 2020 |
Dual regulation of microglia and neurons by Astragaloside IV-mediated mTORC1 suppression promotes functional recovery after acute spinal cord injury.
Topics: Animals; Apoptosis; Autophagy; Cell Polarity; Cells, Cultured; Disease Models, Animal; Female; Inflammation; Macrophages; Mechanistic Target of Rapamycin Complex 1; Microglia; Neurons; Rats; Rats, Sprague-Dawley; Recovery of Function; Saponins; Signal Transduction; Spinal Cord Injuries; Triterpenes | 2020 |
Astragaloside IV inhibits cardiac fibrosis via miR-135a-TRPM7-TGF-β/Smads pathway.
Topics: Animals; Animals, Newborn; Astragalus Plant; Cardiomyopathy, Hypertrophic; Cells, Cultured; Disease Models, Animal; Fibrosis; Humans; Isoproterenol; Male; Medicine, Chinese Traditional; MicroRNAs; Myocardium; Myofibroblasts; Plant Extracts; Plant Roots; Primary Cell Culture; Rats; Rats, Sprague-Dawley; Saponins; Signal Transduction; Smad Proteins; Transforming Growth Factor beta; Triterpenes; TRPM Cation Channels | 2020 |
Astragaloside IV Alleviates Cerebral Ischemia-Reperfusion Injury by Activating the Janus Kinase 2 and Signal Transducer and Activator of Transcription 3 Signaling Pathway.
Topics: Animals; Apoptosis; Brain Ischemia; Disease Models, Animal; Janus Kinase 2; Male; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Reperfusion Injury; Saponins; Signal Transduction; STAT3 Transcription Factor; Superoxide Dismutase; Triterpenes | 2020 |
Astragaloside IV attenuates sepsis-induced intestinal barrier dysfunction via suppressing RhoA/NLRP3 inflammasome signaling.
Topics: ADP Ribose Transferases; Animals; Astragalus propinquus; Botulinum Toxins; Caco-2 Cells; Disease Models, Animal; Drugs, Chinese Herbal; Gene Knockdown Techniques; Humans; Inflammasomes; Injections, Intravenous; Intestinal Mucosa; Male; Mice; NLR Family, Pyrin Domain-Containing 3 Protein; Permeability; rhoA GTP-Binding Protein; RNA, Small Interfering; Saponins; Sepsis; Signal Transduction; Triterpenes | 2020 |
Astragaloside IV Synergizes with Ferulic Acid to Alleviate Hepatic Fibrosis in Bile Duct-Ligated Cirrhotic Rats.
Topics: Animals; Cholestasis; Common Bile Duct; Coumaric Acids; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Hepatic Stellate Cells; Ligation; Liver; Liver Cirrhosis, Biliary; Male; NF-E2-Related Factor 2; Oxidative Stress; Rats, Wistar; Receptors, Transforming Growth Factor beta; Saponins; Signal Transduction; Smad3 Protein; Smad4 Protein; Transforming Growth Factor beta1; Triterpenes | 2020 |
Astragalus polysaccharides and astragaloside IV ameliorates cyclophosphamide-induced mouse model of overactive bladder.
Topics: Animals; Astragalus Plant; Cell Movement; Cell Proliferation; Cyclophosphamide; Disease Models, Animal; Female; Fibroblasts; Humans; Mice; Polysaccharides; Saponins; Triterpenes; Urinary Bladder, Overactive; Urination; Urothelium | 2020 |
Astragaloside IV acts through multi-scale mechanisms to effectively reduce diabetic nephropathy.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Caco-2 Cells; Computational Biology; Diabetic Nephropathies; Disease Models, Animal; Epithelial-Mesenchymal Transition; Gene Regulatory Networks; Humans; Inflammation Mediators; Kidney; Male; Molecular Docking Simulation; Molecular Dynamics Simulation; Oxidative Stress; Protein Interaction Maps; Rats, Sprague-Dawley; Saponins; Triterpenes; Wnt Signaling Pathway | 2020 |
Effect of astragaloside IV on cognitive dysfunction in rats with cerebrally infarcted via TGF-β / Smad signaling pathway.
Topics: Animals; Case-Control Studies; Cerebral Infarction; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Male; Rats; Rats, Sprague-Dawley; Saponins; Severity of Illness Index; Signal Transduction; Smad Proteins; Smad1 Protein; Smad3 Protein; Smad7 Protein; Transforming Growth Factor beta; Triterpenes | 2020 |
Astragaloside IV regulates the HIF/VEGF/Notch signaling pathway through miRNA-210 to promote angiogenesis after ischemic stroke.
Topics: Adult; Animals; Disease Models, Animal; Endothelial Cells; Humans; Hypoxia-Inducible Factor 1; Ischemic Stroke; Male; MicroRNAs; Neovascularization, Pathologic; Rats; Rats, Sprague-Dawley; Receptors, Notch; Saponins; Signal Transduction; Triterpenes; Vascular Endothelial Growth Factor A | 2020 |
Astragaloside-IV regulates endoplasmic reticulum stress-mediated neuronal apoptosis in a murine model of Parkinson's disease via the lincRNA-p21/CHOP pathway.
Topics: Animals; Apoptosis; Cell Line; Cyclin-Dependent Kinase Inhibitor p21; Disease Models, Animal; Endoplasmic Reticulum Stress; Male; Mice, Inbred C57BL; Neurons; Neuroprotective Agents; Parkinson Disease; Protein Stability; RNA, Long Noncoding; Saponins; Signal Transduction; Transcription Factor CHOP; Triterpenes | 2020 |
Astragaloside IV as Potential Antioxidant Against Diabetic Ketoacidosis in Juvenile Mice Through Activating JNK/Nrf2 Signaling Pathway.
Topics: Animals; Antioxidants; Child; Child, Preschool; Diabetic Ketoacidosis; Disease Models, Animal; Drugs, Chinese Herbal; Female; Humans; Male; MAP Kinase Signaling System; Mice; NF-E2-Related Factor 2; Saponins; Signal Transduction; Triterpenes | 2020 |
Astragaloside IV Promotes Antiphotoaging by Enhancing the Proliferation and Paracrine Activity of Adipose-Derived Stem Cells.
Topics: Adipose Tissue; Adult; Animals; Cell Differentiation; Cell Proliferation; Collagen Type I; Culture Media, Conditioned; Dermis; Disease Models, Animal; Down-Regulation; Female; Fibroblasts; Humans; Intercellular Signaling Peptides and Proteins; Light; Matrix Metalloproteinase 1; Mice, Inbred BALB C; Microvessels; Paracrine Communication; Phenotype; Saponins; Skin Aging; Stem Cells; Triterpenes; Ultraviolet Rays; Up-Regulation; Young Adult | 2020 |
Astragaloside IV ameliorates preeclampsia-induced oxidative stress through the Nrf2/HO-1 pathway in a rat model.
Topics: Animals; Blood Pressure; Disease Models, Animal; Female; Glutathione; Glutathione Peroxidase; Heme Oxygenase (Decyclizing); Malondialdehyde; NF-E2-Related Factor 2; Oxidative Stress; Placenta; Placenta Growth Factor; Pre-Eclampsia; Pregnancy; Rats; Rats, Wistar; Saponins; Signal Transduction; Triterpenes; Vascular Endothelial Growth Factor Receptor-1 | 2020 |
Astragaloside IV alleviates lipopolysaccharide-induced preeclampsia-like phenotypes via suppressing the inflammatory responses.
Topics: Animals; Blood Pressure; Cytokines; Disease Models, Animal; Female; Heart Rate; Inflammation; Lipopolysaccharides; NF-kappa B; Phenotype; Placenta; Placenta Growth Factor; Pre-Eclampsia; Pregnancy; Pregnancy Outcome; Proteinuria; Rats, Sprague-Dawley; RNA, Messenger; Saponins; Toll-Like Receptor 4; Triterpenes; Urine; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2021 |
Astragaloside IV and echinacoside benefit neuronal properties via direct effects and through upregulation of SOD1 astrocyte function in vitro.
Topics: Amyotrophic Lateral Sclerosis; Animals; Astragalus propinquus; Astrocytes; Cistanche; Disease Models, Animal; Excitatory Amino Acid Transporter 2; Glycosides; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Neurons; Saponins; Superoxide Dismutase-1; Triterpenes; Up-Regulation | 2021 |
Astragaloside IV alleviates PM2.5-induced lung injury in rats by modulating TLR4/MyD88/NF-κB signalling pathway.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Cytokines; Disease Models, Animal; Inflammation Mediators; Lung; Lung Injury; Male; Myeloid Differentiation Factor 88; NF-kappa B; Oxidative Stress; Particulate Matter; Pulmonary Edema; Rats, Sprague-Dawley; Saponins; Signal Transduction; Toll-Like Receptor 4; Triterpenes | 2021 |
Astragaloside IV attenuates cerebral ischemia‑reperfusion injury in rats through the inhibition of calcium‑sensing receptor‑mediated apoptosis.
Topics: Animals; Apoptosis; Cerebrovascular Disorders; Disease Models, Animal; Male; Rats; Rats, Sprague-Dawley; Receptors, Calcium-Sensing; Reperfusion Injury; Saponins; Triterpenes | 2021 |
Astragaloside IV promotes microglia/macrophages M2 polarization and enhances neurogenesis and angiogenesis through PPARγ pathway after cerebral ischemia/reperfusion injury in rats.
Topics: Animals; Brain Injuries; Cell Polarity; Disease Models, Animal; Infarction, Middle Cerebral Artery; Macrophages; Male; Microglia; Neovascularization, Physiologic; Neurogenesis; PPAR gamma; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Saponins; Triterpenes | 2021 |
Astragaloside IV protects against iron loading-induced abnormal differentiation of bone marrow mesenchymal stem cells (BMSCs).
Topics: Adipogenesis; Animals; Bone Marrow Cells; Cell Differentiation; Cell Proliferation; Cell Survival; Disease Models, Animal; Female; Homeostasis; Iron; Mesenchymal Stem Cells; Mice; Osteogenesis; Osteoporosis; Saponins; Triterpenes; X-Ray Microtomography | 2021 |
Astragaloside alleviates alcoholic fatty liver disease by suppressing oxidative stress.
Topics: Animals; Apoptosis; Cell Line; Disease Models, Animal; Fatty Liver, Alcoholic; Inflammation; Lipid Metabolism; Liver Function Tests; Male; NF-kappa B; Oxidative Stress; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Saponins; Signal Transduction; Triterpenes | 2021 |
Astragaloside IV Attenuates Polymicrobial Sepsis-Induced Cardiac Dysfunction in Rats via IKK/NF-κB Pathway.
Topics: Animals; Disease Models, Animal; Heart Diseases; NF-kappa B; Rats; Rats, Sprague-Dawley; Saponins; Sepsis; Triterpenes; Tumor Necrosis Factor-alpha | 2021 |
Astragaloside IV Ameliorates Cognitive Impairment and Neuroinflammation in an Oligomeric Aβ Induced Alzheimer's Disease Mouse Model via Inhibition of Microglial Activation and NADPH Oxidase Expression.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Astragalus Plant; Cognitive Dysfunction; Cytokines; Disease Models, Animal; Drugs, Chinese Herbal; Hippocampus; Male; Maze Learning; Mice, Inbred ICR; Microglia; NADP; NADPH Oxidases; Neuroinflammatory Diseases; Neurons; Neuroprotective Agents; Phytotherapy; Reactive Oxygen Species; Saponins; Triterpenes | 2021 |
Astragaloside IV alleviates heart failure via activating PPARα to switch glycolysis to fatty acid β-oxidation.
Topics: Animals; Apoptosis Regulatory Proteins; Calcium; Cardiotonic Agents; Cell Respiration; Disease Models, Animal; Energy Metabolism; Enzyme Activation; Fatty Acids; Gene Expression Regulation; Glucose; Glycolysis; Heart Failure; Heart Function Tests; Hemodynamics; Male; Mice; Mitochondria, Heart; Oxidation-Reduction; PPAR alpha; Saponins; Triterpenes | 2017 |
Protective effects of astragaloside IV against ovalbumin-induced allergic rhinitis are mediated by T-box protein expressed in T cells/GATA-3 and forkhead box protein 3/retinoic acid-related orphan nuclear receptor γt.
Topics: Allergens; Animals; Biomarkers; Dexamethasone; Disease Models, Animal; DNA-Binding Proteins; Female; GATA3 Transcription Factor; Gene Expression Regulation; Immunoglobulin E; Male; Mice; Nasal Mucosa; Nerve Tissue Proteins; Nuclear Proteins; Nuclear Receptor Subfamily 1, Group F, Member 3; Ovalbumin; Protective Agents; Rhinitis, Allergic; RNA, Messenger; Saponins; Spleen; T-Box Domain Proteins; T-Lymphocyte Subsets; Triterpenes | 2017 |
The effect of Astragaloside IV on ethanol-induced gastric mucosal injury in rats: Involvement of inflammation.
Topics: Animals; Anti-Inflammatory Agents; Cells, Cultured; Cytokines; Disease Models, Animal; Ethanol; Gastritis; Humans; Inflammation Mediators; Intestines; Male; Neutrophils; NF-kappa B; Omeprazole; Peroxidase; Rats; Rats, Sprague-Dawley; Saponins; TNF Receptor-Associated Factor 2; Triterpenes; Tumor Necrosis Factor-alpha | 2017 |
Astragaloside IV attenuates penicillin-induced epilepsy via inhibiting activation of the MAPK signaling pathway.
Topics: Animals; Astrocytes; Cell Proliferation; Disease Models, Animal; Epilepsy; Humans; Mitogen-Activated Protein Kinase Kinases; NF-kappa B; Penicillins; Primary Cell Culture; Rats; Reactive Oxygen Species; Saponins; Signal Transduction; Triterpenes | 2018 |
Astragaloside IV inhibits ventricular remodeling and improves fatty acid utilization in rats with chronic heart failure.
Topics: Animals; Benzazepines; Chronic Disease; Chymases; Disease Models, Animal; Energy Metabolism; Fatty Acids; Heart Failure; Heart Ventricles; Humans; Myocardium; Myocytes, Cardiac; PPAR alpha; Rats; RNA, Messenger; Saponins; Triterpenes; Ventricular Remodeling | 2018 |
Preventive effects of astragaloside IV and its active sapogenin cycloastragenol on cardiac fibrosis of mice by inhibiting the NLRP3 inflammasome.
Topics: Animals; Cardiovascular Diseases; Cells, Cultured; Disease Models, Animal; Drugs, Chinese Herbal; Fibroblasts; Fibrosis; Heart; Humans; Inflammasomes; Isoproterenol; Male; Mice; Mice, Inbred BALB C; Myocardium; NLR Family, Pyrin Domain-Containing 3 Protein; Primary Cell Culture; Rats; Rats, Sprague-Dawley; Sapogenins; Saponins; Triterpenes | 2018 |
Protective Effects of Astragaloside IV on Delayed Cerebral Vasospasm in an Experimental Rat Model of Subarachnoid Hemorrhage.
Topics: Animals; Disease Models, Animal; Male; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Saponins; Subarachnoid Hemorrhage; Treatment Outcome; Triterpenes; Vasospasm, Intracranial | 2018 |
Astragaloside IV Attenuates Acetaminophen-Induced Liver Injuries in Mice by Activating the Nrf2 Signaling Pathway.
Topics: Acetaminophen; Animals; Antioxidants; Biopsy; Chemical and Drug Induced Liver Injury; Cytokines; Disease Models, Animal; Inflammation Mediators; Liver Function Tests; Male; Mice; Molecular Structure; NF-E2-Related Factor 2; Oxidative Stress; Saponins; Signal Transduction; Triterpenes | 2018 |
Effect of Combined Use of Astragaloside IV (AsIV) and Atorvastatin (AV) on Expression of PPAR-γ and Inflammation-Associated Cytokines in Atherosclerosis Rats.
Topics: Animals; Atherosclerosis; Atorvastatin; China; Cytokines; Disease Models, Animal; Drug Therapy, Combination; Inflammation; Interleukin-18; Interleukin-6; Lipoproteins, HDL; Lipoproteins, LDL; Male; PPAR gamma; Rats; Rats, Sprague-Dawley; Saponins; Signal Transduction; Triterpenes; Tumor Necrosis Factor-alpha | 2018 |
Astragaloside IV represses high glucose-induced mesangial cells activation by enhancing autophagy via SIRT1 deacetylation of NF-κB p65 subunit.
Topics: Acetylation; Animals; Autophagy; Cell Proliferation; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Glucose; Male; Mesangial Cells; Mice; Mice, Inbred C57BL; Saponins; Sirtuin 1; Structure-Activity Relationship; Transcription Factor RelA; Triterpenes | 2018 |
Astragaloside IV reversed the autophagy and oxidative stress induced by the intestinal microbiota of AIS in mice.
Topics: Animals; Antioxidants; Autophagy; Autophagy-Related Protein 12; Bacteria; Beclin-1; Brain; Disease Models, Animal; Fatty Acids; Feces; Gastrointestinal Microbiome; Genetic Vectors; Glutathione; Homocysteine; Ischemic Attack, Transient; Male; Malondialdehyde; Mice; Mice, Inbred C57BL; Microtubule-Associated Proteins; NADPH Oxidase 2; NADPH Oxidase 4; Oxidative Stress; Reactive Oxygen Species; Saponins; Stroke; Superoxide Dismutase; Triterpenes | 2018 |
Association of astragaloside IV-inhibited autophagy and mineralization in vascular smooth muscle cells with lncRNA H19 and DUSP5-mediated ERK signaling.
Topics: Animals; Atherosclerosis; Autophagy; Autophagy-Related Proteins; Cells, Cultured; Disease Models, Animal; Dual-Specificity Phosphatases; Extracellular Signal-Regulated MAP Kinases; Humans; Mice, Inbred C57BL; Mice, Knockout, ApoE; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phosphorylation; Plaque, Atherosclerotic; RNA, Long Noncoding; Saponins; Signal Transduction; TOR Serine-Threonine Kinases; Triterpenes; Vascular Calcification | 2019 |
Astragaloside IV ameliorates endoplasmic reticulum stress‑induced apoptosis of Aβ25‑35‑treated PC12 cells by inhibiting the p38 MAPK signaling pathway.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Cell Survival; Disease Models, Animal; Endoplasmic Reticulum Stress; Humans; Malondialdehyde; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; PC12 Cells; Peptide Fragments; Rats; Reactive Oxygen Species; Saponins; Signal Transduction; Superoxide Dismutase; Triterpenes | 2019 |
Astragaloside IV inhibits glucose-induced epithelial-mesenchymal transition of podocytes through autophagy enhancement via the SIRT-NF-κB p65 axis.
Topics: Animals; Autophagy; Cell Line; Diabetic Nephropathies; Disease Models, Animal; Epithelial-Mesenchymal Transition; Glucose; Kidney Function Tests; Mice; Models, Biological; Podocytes; Saponins; Sirtuin 1; Transcription Factor RelA; Treatment Outcome; Triterpenes | 2019 |
Astragaloside IV alleviates heart failure by promoting angiogenesis through the JAK-STAT3 pathway.
Topics: Angiogenesis Inducing Agents; Animals; Coronary Vessels; Disease Models, Animal; Heart Failure; Human Umbilical Vein Endothelial Cells; Humans; Janus Kinases; Kaplan-Meier Estimate; Male; Myocardial Infarction; Myocardium; Platelet Endothelial Cell Adhesion Molecule-1; Random Allocation; Rats; Rats, Sprague-Dawley; Saponins; Signal Transduction; STAT3 Transcription Factor; Triterpenes; Weight Gain | 2019 |
Astragaloside IV reduces cardiomyocyte apoptosis in a murine model of coxsackievirus B3-induced viral myocarditis.
Topics: Animals; Apoptosis; Astragalus propinquus; Coxsackievirus Infections; Disease Models, Animal; Enterovirus B, Human; Male; Mice; Mice, Inbred C57BL; Myocarditis; Myocytes, Cardiac; Protective Agents; Random Allocation; Saponins; Triterpenes | 2019 |
Astragalus injection protects cerebral ischemic injury by inhibiting neuronal apoptosis and the expression of JNK3 after cerebral ischemia reperfusion in rats.
Topics: Animals; Apoptosis; Brain Ischemia; Disease Models, Animal; Down-Regulation; Drugs, Chinese Herbal; Male; Mitogen-Activated Protein Kinase 10; Neurons; Neuroprotective Agents; Rats; Rats, Wistar; Reperfusion Injury; Saponins; Triterpenes | 2013 |
Astragaloside IV attenuates experimental autoimmune encephalomyelitis of mice by counteracting oxidative stress at multiple levels.
Topics: Animals; Antioxidants; Apoptosis Regulatory Proteins; CD11b Antigen; Cell Line; Cytokines; Demyelinating Diseases; Disease Models, Animal; Disease Progression; Drugs, Chinese Herbal; Encephalomyelitis, Autoimmune, Experimental; Female; Forkhead Transcription Factors; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Humans; Inflammation; Mice; Multiple Sclerosis; Nerve Tissue Proteins; Nitric Oxide Synthase Type II; Nuclear Receptor Subfamily 1, Group F, Member 3; Oxidative Stress; Reactive Oxygen Species; RNA, Messenger; Saponins; T-Box Domain Proteins; Th1 Cells; Th17 Cells; Triterpenes | 2013 |
Inhibition of human neutrophil elastase by pentacyclic triterpenes.
Topics: Animals; Disease Models, Animal; Enzyme Inhibitors; Female; Glycine; Humans; Kinetics; Leukocyte Elastase; Mice, Inbred BALB C; Molecular Docking Simulation; Pentacyclic Triterpenes; Pneumonia; Proton Magnetic Resonance Spectroscopy; Saponins; Smoking; Sulfonamides; Triterpenes; Ursolic Acid | 2013 |
Beneficial effects of Astragaloside IV for hair loss via inhibition of Fas/Fas L-mediated apoptotic signaling.
Topics: Alopecia; Animals; Apoptosis; Caspase 3; Disease Models, Animal; Fas Ligand Protein; fas Receptor; Female; Hair Follicle; I-kappa B Proteins; Interleukin-1beta; Mice; Mitogen-Activated Protein Kinases; NF-kappa B; NF-KappaB Inhibitor alpha; Saponins; Signal Transduction; Triterpenes; Tumor Necrosis Factor-alpha | 2014 |
Astragaloside IV inhibits the up-regulation of Wnt/β-catenin signaling in rats with unilateral ureteral obstruction.
Topics: Administration, Oral; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Male; Rats; Rats, Sprague-Dawley; Saponins; Triterpenes; Up-Regulation; Ureteral Obstruction; Wnt Signaling Pathway | 2014 |
Astragaloside IV inhibits renal tubulointerstitial fibrosis by blocking TGF-β/Smad signaling pathway in vivo and in vitro.
Topics: Animals; Disease Models, Animal; Fibrosis; Gene Expression Profiling; Kidney; Kidney Diseases; Kidney Function Tests; Rats, Sprague-Dawley; Saponins; Severity of Illness Index; Signal Transduction; Smad7 Protein; Transforming Growth Factor beta; Triterpenes | 2014 |
Protective effects of astragaloside IV against ovalbumin-induced lung inflammation are regulated/mediated by T-bet/GATA-3.
Topics: Animals; Asthma; Astragalus propinquus; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Female; GATA3 Transcription Factor; Interferon-gamma; Interleukin-4; Interleukin-5; Male; Mice; Mice, Inbred BALB C; Ovalbumin; Pneumonia; RNA, Messenger; Saponins; Triterpenes | 2014 |
Astragaloside improves outcomes of traumatic brain injury in rats by reducing microglia activation.
Topics: Animals; Apoptosis; Brain; Brain Injuries; Disease Models, Animal; Drugs, Chinese Herbal; Injections, Intraperitoneal; Male; Microglia; Motor Activity; Phytotherapy; Rats, Sprague-Dawley; Saponins; Triterpenes; Tumor Necrosis Factor-alpha | 2014 |
Anti-fibrotic effects of Astragaloside IV in systemic sclerosis.
Topics: Animals; Disease Models, Animal; Fibroblasts; Fibrosis; Humans; Mice; RNA, Messenger; Saponins; Scleroderma, Systemic; Smad3 Protein; Transforming Growth Factor beta; Triterpenes | 2014 |
EGFR mediates astragaloside IV-induced Nrf2 activation to protect cortical neurons against in vitro ischemia/reperfusion damages.
Topics: Animals; Antioxidants; Cerebral Cortex; Disease Models, Animal; Drugs, Chinese Herbal; ErbB Receptors; Gene Knockdown Techniques; Mice; Neurons; Neuroprotective Agents; NF-E2-Related Factor 2; Primary Cell Culture; Reactive Oxygen Species; Reperfusion Injury; RNA, Messenger; Saponins; Transcriptional Activation; Triterpenes | 2015 |
Astragaloside IV ameliorates acute pancreatitis in rats by inhibiting the activation of nuclear factor-κB.
Topics: Amylases; Animals; Antioxidants; Cytokines; Disease Models, Animal; Enzyme Activation; Inflammation Mediators; Lipase; Male; Necrosis; NF-kappa B; Pancreatitis; Peroxidase; Protein Transport; Rats; Saponins; Triterpenes | 2015 |
Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress.
Topics: Analysis of Variance; Animals; Apoptosis; Blotting, Western; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Male; Podocytes; Proteinuria; Random Allocation; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Reference Values; Saponins; Streptozocin; Triterpenes; Urinalysis | 2015 |
Antinociceptive activity of astragaloside IV in the animal model of chronic constriction injury.
Topics: Analgesics; Animals; Body Weight; Chronic Pain; Constriction, Pathologic; Disease Models, Animal; Ganglia, Spinal; Hot Temperature; Hyperalgesia; Male; Motor Activity; Necrosis; Neural Conduction; Neuralgia; Rats, Sprague-Dawley; Saponins; Sciatic Nerve; Touch; Triterpenes | 2015 |
Therapeutic angiogenesis in ischemic muscles after local injection of fragmented fibers with loaded traditional Chinese medicine.
Topics: Animals; Cell Line; Cell Proliferation; Disease Models, Animal; Drug Carriers; Hindlimb; Human Umbilical Vein Endothelial Cells; Humans; Immunohistochemistry; Ischemia; Medicine, Chinese Traditional; Mice, Nude; Muscle, Skeletal; Neovascularization, Physiologic; Saponins; Triterpenes | 2015 |
Inhibition of RANKL-induced osteoclastogenesis through the suppression of the ERK signaling pathway by astragaloside IV and attenuation of titanium-particle-induced osteolysis.
Topics: Animals; Cell Line; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Ligands; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Osteoclasts; Osteogenesis; Osteolysis; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Saponins; Titanium; Triterpenes | 2015 |
Astragalosides promote angiogenesis via vascular endothelial growth factor and basic fibroblast growth factor in a rat model of myocardial infarction.
Topics: Angiogenesis Inducing Agents; Animals; Coronary Vessels; Disease Models, Animal; Drug Evaluation, Preclinical; Fibroblast Growth Factor 2; Gene Expression; Male; Microvessels; Myocardial Infarction; Myocardium; Neovascularization, Physiologic; Rats, Wistar; Saponins; Triterpenes; Vascular Endothelial Growth Factor A | 2015 |
Effects of the Combination of the Main Active Components of Astragalus and Panax notoginseng on Inflammation and Apoptosis of Nerve Cell after Cerebral Ischemia-Reperfusion.
Topics: Animals; Apoptosis; Astragalus Plant; Brain Ischemia; CA1 Region, Hippocampal; Cell Survival; Disease Models, Animal; Drug Combinations; Endoplasmic Reticulum Chaperone BiP; Ginsenosides; Inflammation; Janus Kinase 1; Male; Mice, Inbred C57BL; Neurons; Neuroprotective Agents; NF-kappa B; Panax notoginseng; Phytotherapy; Reperfusion Injury; Saponins; STAT1 Transcription Factor; Triterpenes | 2015 |
Astragaloside IV inhibits microglia activation via glucocorticoid receptor mediated signaling pathway.
Topics: Animals; Anti-Inflammatory Agents; Binding Sites; Binding, Competitive; Cytokines; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Humans; Inflammation Mediators; Ligands; Lipopolysaccharides; Mice; Microglia; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; NF-kappa B; Protein Binding; Receptors, Glucocorticoid; Saponins; Signal Transduction; Toll-Like Receptors; Triterpenes | 2016 |
A positive correlation exists between neurotrauma and TGF-β1-containing microglia in rats.
Topics: Animals; Brain; Brain Contusion; Brain Injuries, Traumatic; Disease Models, Animal; Drugs, Chinese Herbal; Immunohistochemistry; Male; Microglia; Rats; Rats, Sprague-Dawley; Saponins; Transforming Growth Factor beta1; Triterpenes | 2016 |
[Effect and mechanism of traditional Chinese herbs against Aβ expression in brain tissues of mice with Alzheimer's disease].
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals; Benzyl Alcohols; Brain; Disease Models, Animal; Glucosides; Hippocampus; Memory; Mice; Mice, Transgenic; Monoterpenes; Plaque, Amyloid; Random Allocation; Saponins; Triterpenes | 2016 |
Astragaloside IV attenuates cognitive impairments induced by transient cerebral ischemia and reperfusion in mice via anti-inflammatory mechanisms.
Topics: Animals; Anti-Inflammatory Agents; Cognitive Dysfunction; Disease Models, Animal; Inflammation; Ischemic Attack, Transient; Male; Mice; Neuroprotective Agents; NF-kappa B; Reperfusion; Saponins; Toll-Like Receptor 4; Triterpenes | 2017 |
Astragaloside IV ameliorates 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis implicating regulation of energy metabolism.
Topics: Actins; Animals; Biomarkers; Cell Count; Colitis; Colon; Disease Models, Animal; Dose-Response Relationship, Drug; Energy Metabolism; Immunohistochemistry; Inflammatory Bowel Diseases; Intestinal Mucosa; Proteolysis; Rats; Regional Blood Flow; Saponins; Stem Cells; Tight Junction Proteins; Trinitrobenzenesulfonic Acid; Triterpenes | 2017 |
Synergistic Inhibitory Effect of Traditional Chinese Medicine Astragaloside IV and Curcumin on Tumor Growth and Angiogenesis in an Orthotopic Nude-Mouse Model of Human Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Growth Processes; Curcumin; Disease Models, Animal; Down-Regulation; Drug Synergism; Hep G2 Cells; Heterografts; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Random Allocation; Saponins; Triterpenes | 2017 |
Effects of astragaloside IV on IFN-gamma level and prolonged airway dysfunction in a murine model of chronic asthma.
Topics: Animals; Asthma; Astragalus Plant; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Chronic Disease; Collagen; Disease Models, Animal; Drugs, Chinese Herbal; Female; Immune System; Inflammation; Interferon-gamma; Mice; Mice, Inbred BALB C; Mucus; Ovalbumin; Phytotherapy; Plant Roots; Respiratory System; Saponins; Triterpenes | 2011 |
Astragaloside IV attenuates impulse noise-induced trauma in guinea pig.
Topics: Administration, Oral; Animals; Auditory Threshold; Disease Models, Animal; Drugs, Chinese Herbal; Evoked Potentials, Auditory, Brain Stem; Guinea Pigs; Hearing Loss, Noise-Induced; Nitric Oxide Synthase Type II; Reactive Oxygen Species; Saponins; Treatment Outcome; Triterpenes | 2011 |
Synergistic protective effect of astragaloside IV-tetramethylpyrazine against cerebral ischemic-reperfusion injury induced by transient focal ischemia.
Topics: Animals; Astragalus Plant; Cardiovascular Agents; Caspase 3; Disease Models, Animal; Drug Synergism; Glucose; Hippocampus; Ischemic Attack, Transient; Male; Malondialdehyde; Neuroprotective Agents; Nimodipine; Nitric Oxide Synthase Type II; Phytotherapy; Plant Extracts; Positron-Emission Tomography; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Random Allocation; Rats; Rats, Sprague-Dawley; Reperfusion Injury; RNA, Messenger; Saponins; Superoxide Dismutase; Triterpenes | 2012 |
Astragaloside IV inhibits apoptotic cell death in the guinea pig cochlea exposed to impulse noise.
Topics: Aldehydes; Animals; Apoptosis; Caspase 3; Cell Death; Cochlea; Disease Models, Animal; Drugs, Chinese Herbal; Evoked Potentials, Auditory, Brain Stem; Follow-Up Studies; Guinea Pigs; Hearing Loss, Noise-Induced; Immunohistochemistry; Noise; Reactive Oxygen Species; Saponins; Treatment Outcome; Triterpenes | 2012 |
Astragaloside IV protects against ischemic brain injury in a murine model of transient focal ischemia.
Topics: Animals; Brain Chemistry; Brain Ischemia; Cardiotonic Agents; Catalase; Cerebral Infarction; Disease Models, Animal; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Glutathione Peroxidase; Infarction, Middle Cerebral Artery; Lipid Peroxidation; Male; Malondialdehyde; Mice; Mice, Inbred C57BL; Reperfusion Injury; Saponins; Superoxide Dismutase; Triterpenes | 2004 |